An observational study in Long COVID, Major Depressive Disorder and Major Depressive Episode, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Centre for Addiction and Mental Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.
Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is one of 8 that started in 2023, is one of 7 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 24th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:
York University · Sites in Canada
Ages 18–65
ParagonClinicals Inc. · Sites in Canada
Ages 19+
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 1
First in 2021; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 82 across the 33 interventional studies, 120 across the 7 observational. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 40 have an industry lead sponsor. The 10 most frequent:
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
Centre for Addiction and Mental Health has 2 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07374562Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-QuébecStellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial | 2027-02 |
| NCT04736732Emilia Falcone, MDInstitut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic | 2027-05-04 |
| NCT07312409York UniversityDoes Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID? | 2027-06-30 |
| NCT06082518Sunnybrook Health Sciences CentreImproving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Participants will undergo two positron emission tomography (PET) scans, one [11C]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one [18F]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan.
The main question[s] it aims to answer are:
Recovered from mild to moderate COVID-19 respiratory symptoms with subsequent onset of COVID-DNP
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
Other: [11C]DTBZ PET scan · Other: [18F]SDM8 PET scan · Other: MRI scan
Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
Other: [11C]DTBZ PET scan · Other: [18F]SDM8 PET scan · Other: MRI scan
One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
One MRI scan
Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND)
The investigators will determine if VMAT2 BPND is changed in ventral striatum and dorsal putamen in COVID-DNP.
Time frame: within 3 to 4 weeks after initiation of screening
Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT)
The investigators will determine if SV2A VT is changed in ventral striatum and dorsal putamen in COVID-DNP
Time frame: within 3 to 4 weeks after initiation of screening
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Sep 2028, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Centre for Addiction and Mental Health →